Tapan Kadia, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, describes the results of a Phase I trial (NCT03773393) of adoptive therapy with allogeneic cord blood T-regulatory cells (Tregs) for bone marrow failure (BMF) syndromes. Since cord blood Tregs are immune privileged and highly proliferative they can suppress inflammation, theorized to be beneficial for the inflammatory bone marrow microenvironment seen in BMF disorders. CK0801, an allogenic cord blood Treg product, was given to six patients with aplastic anemia or primary myelofibrosis, treated in a 3+3 design. The two dose levels trialled were well tolerated and clinical benefits were seen. The maximum tolerated dose was not reached and determination of the optimal Treg cell dose is ongoing. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.